Charles Schwab’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-37,596
| Closed | -$47.7K | – | 3609 |
|
|
2023
Q3 | $47.7K | Hold |
37,596
| – | – | ﹤0.01% | 3411 |
|
|
2023
Q2 | $12.3K | Hold |
37,596
| – | – | ﹤0.01% | 3590 |
|
|
2023
Q1 | $16.2K | Hold |
37,596
| – | – | ﹤0.01% | 3522 |
|
|
2022
Q4 | $19.9K | Hold |
37,596
| – | – | ﹤0.01% | 3503 |
|
|
2022
Q3 | $28K | Hold |
37,596
| – | – | ﹤0.01% | 3452 |
|
|
2022
Q2 | $43K | Buy |
+37,596
| New | +$47.9K | ﹤0.01% | 3414 |
|
|
2022
Q1 | – | Sell |
-18,093
| Closed | -$53K | – | 3640 |
|
|
2021
Q4 | $53K | Hold |
18,093
| – | – | ﹤0.01% | 3510 |
|
|
2021
Q3 | $77K | Hold |
18,093
| – | – | ﹤0.01% | 3409 |
|
|
2021
Q2 | $96K | Buy |
+18,093
| New | +$87K | ﹤0.01% | 3293 |
|
|
2020
Q2 | – | Sell |
-57,333
| Closed | -$220K | – | 3375 |
|
|
2020
Q1 | $220K | Hold |
57,333
| – | – | ﹤0.01% | 2990 |
|
|
2019
Q4 | $347K | Hold |
57,333
| – | – | ﹤0.01% | 2941 |
|
|
2019
Q3 | $434K | Buy |
57,333
+4,645
| +9% | +$52.4K | ﹤0.01% | 2860 |
|
|
2019
Q2 | $714K | Buy |
+52,688
| New | +$608K | ﹤0.01% | 2687 |
|
|
2018
Q2 | – | Sell |
-19,200
| Closed | -$167K | – | 3162 |
|
|
2018
Q1 | $167K | Hold |
19,200
| – | – | ﹤0.01% | 3013 |
|
|
2017
Q4 | $241K | Hold |
19,200
| – | – | ﹤0.01% | 2942 |
|
|
2017
Q3 | $161K | Hold |
19,200
| – | – | ﹤0.01% | 3039 |
|
|
2017
Q2 | $326K | Buy |
+19,200
| New | +$382K | ﹤0.01% | 2834 |
|
Charles Schwab's ZYNE Position: Q4 2023 in Review
Charles Schwab sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 37,596 shares — an estimated $47.7K sold.
Charles Schwab first reported a position in ZYNE in Q2 2017 and held it in 17 quarters. The position peaked at $714K in Q2 2019. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Charles Schwab reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Charles Schwab sold 37,596 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $47.7K.
- Charles Schwab first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 17 quarters.
- Charles Schwab's Zynerba Pharmaceuticals, Inc position peaked at $714K in Q2 2019.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Charles Schwab's 13F filing for Q4 2023, filed 6 Feb 2024.